Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
Identifieur interne : 003C20 ( PubMed/Corpus ); précédent : 003C19; suivant : 003C21Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
Auteurs : P J Reading ; A K Luce ; I G MckeithSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2001.
English descriptors
- KwdEn :
- Aged, Carbamates (therapeutic use), Caregivers (psychology), Cognition Disorders (drug therapy), Cognition Disorders (etiology), Female, Follow-Up Studies, Hallucinations (drug therapy), Humans, Male, Middle Aged, Neuroprotective Agents (therapeutic use), Parkinson Disease (psychology), Phenylcarbamates, Psychotic Disorders (drug therapy), Psychotic Disorders (etiology), Stress, Psychological, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Carbamates, Neuroprotective Agents.
- drug therapy : Cognition Disorders, Hallucinations, Psychotic Disorders.
- etiology : Cognition Disorders, Psychotic Disorders.
- psychology : Caregivers, Parkinson Disease.
- Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Phenylcarbamates, Stress, Psychological, Treatment Outcome.
Abstract
This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug.
PubMed: 11748755
Links to Exploration step
pubmed:11748755Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.</title>
<author><name sortKey="Reading, P J" sort="Reading, P J" uniqKey="Reading P" first="P J" last="Reading">P J Reading</name>
<affiliation><nlm:affiliation>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Luce, A K" sort="Luce, A K" uniqKey="Luce A" first="A K" last="Luce">A K Luce</name>
</author>
<author><name sortKey="Mckeith, I G" sort="Mckeith, I G" uniqKey="Mckeith I" first="I G" last="Mckeith">I G Mckeith</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2001">2001</date>
<idno type="RBID">pubmed:11748755</idno>
<idno type="pmid">11748755</idno>
<idno type="wicri:Area/PubMed/Corpus">003C20</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.</title>
<author><name sortKey="Reading, P J" sort="Reading, P J" uniqKey="Reading P" first="P J" last="Reading">P J Reading</name>
<affiliation><nlm:affiliation>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Luce, A K" sort="Luce, A K" uniqKey="Luce A" first="A K" last="Luce">A K Luce</name>
</author>
<author><name sortKey="Mckeith, I G" sort="Mckeith, I G" uniqKey="Mckeith I" first="I G" last="Mckeith">I G Mckeith</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001" type="published">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Carbamates (therapeutic use)</term>
<term>Caregivers (psychology)</term>
<term>Cognition Disorders (drug therapy)</term>
<term>Cognition Disorders (etiology)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Hallucinations (drug therapy)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinson Disease (psychology)</term>
<term>Phenylcarbamates</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Psychotic Disorders (etiology)</term>
<term>Stress, Psychological</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Carbamates</term>
<term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cognition Disorders</term>
<term>Hallucinations</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Caregivers</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Phenylcarbamates</term>
<term>Stress, Psychological</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11748755</PMID>
<DateCreated><Year>2001</Year>
<Month>12</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2002</Year>
<Month>01</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>16</Volume>
<Issue>6</Issue>
<PubDate><Year>2001</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.</ArticleTitle>
<Pagination><MedlinePgn>1171-4</MedlinePgn>
</Pagination>
<Abstract><AbstractText>This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug.</AbstractText>
<CopyrightInformation>Copyright 2001 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reading</LastName>
<ForeName>P J</ForeName>
<Initials>PJ</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Luce</LastName>
<ForeName>A K</ForeName>
<Initials>AK</Initials>
</Author>
<Author ValidYN="Y"><LastName>McKeith</LastName>
<ForeName>I G</ForeName>
<Initials>IG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>123441-03-2</RegistryNumber>
<NameOfSubstance UI="C072506">rivastigmine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002219">Carbamates</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D017028">Caregivers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006212">Hallucinations</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D048448">Phenylcarbamates</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011618">Psychotic Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D013315">Stress, Psychological</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year>
<Month>12</Month>
<Day>19</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2002</Year>
<Month>1</Month>
<Day>26</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2001</Year>
<Month>12</Month>
<Day>19</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11748755</ArticleId>
<ArticleId IdType="pii">10.1002/mds.1204</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C20 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003C20 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:11748755 |texte= Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:11748755" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |